The invention relates to a novel biotechnological process for preparing 4,4,4-trifluoro-3(R)-hydroxybutyric acid derivatives of the general formula

4,4,4-trifluoro-3(R)-hydroxybutyric acid derivatives such as ethyl 4,4,4-trifluoro-3(R)-hydroxybutyrate are important intermediates for preparing Befloxatone, a monomine oxidase A inhibitor (EP-A-0 736 606).

On page 2, replace the paragraph on line11-29, with the following paragraph:

According to the invention, the process is carried out by a trifluoroacetoacetic acid derivative of the general formula

$$F_3C$$
  $R^1$ 

in which

R1 is  $-OR^2$ , in which  $R^2$  is hydrogen,  $C_{1-10}$ -alkyl,  $C_{2-10}$ -alkenyl,  $C_{3-8}$ -cycloalkyl, aryl, alkoxyalkyl or alkoxyalkoxyalkyl,

-NR $^3$ R $^4$ , in which R $^3$  and R $^4$  are identical or different and represent hydrogen,  $C_{1-10}$ -alkyl  $C_{2-10}$ -alkyl,  $C_{2-10}$ -alkenyl,  $C_{3-8}$ -cycloalkyl or aryl,

-SR $^5$ , in which R $^5$  is hydrogen,  $C_{1\text{-}10}\text{-}alkyl$ ,  $C_{2\text{-}10}\text{-}alkenyl$ , aryl or  $C_{3\text{-}8}\text{-}$  cycloalkyl,

being converted by means of microorganisms which are able to reduce a carbonyl function, or by means of a cell-free enzyme extract of these microorganisms, into the compound of the general

formula

I

Œ